Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00534989

Enrollment

Registered

2007-09-26

Start date

2007-09-30

Completion date

2013-12-31

Last updated

2015-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Non-Hodgkin, Hodgkin Disease

Keywords

NHL and HD

Brief summary

Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma or Hodgkin's Disease

Interventions

PROCEDUREFDG PET

FDG PET

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with NHL and HD undergoing HDC and ASCT

Design outcomes

Primary

Measure	Time frame
Prognosis	overall

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026